Business Context and Reporting Period
This Form 8-K is filed by Tocagen Inc. (not Forte Biosciences, Inc., as indicated in the metadata) on February 7, 2018. The report details executive compensation adjustments, including base salary increases and target bonus approvals for fiscal year 2018, as well as the execution of amended employment agreements for key officers.
Key Financial Metrics and Compensation
The filing does not provide revenue, profit, cash flow, or debt metrics. It focuses exclusively on executive compensation figures approved by the Board and Compensation Committee.
| Executive Officer | 2018 Base Salary | 2018 Target Bonus | 2017 Cash Bonus Paid |
|---|---|---|---|
| Martin J. Duvall (CEO) | $515,000 | 50% | $265,462 |
| Harry E. Gruber, M.D. (President) | $365,000 | 40% | $172,028 |
| Asha Das, M.D. (CMO) | $380,000 | 40% | $140,166 |
| Mark Foletta (CFO) | $380,000 | 40% | $145,088 |
Salary increases are effective March 1, 2018.
Material Changes
- Salary Increases: Base salaries for the CEO, CFO, and CMO were increased effective March 1, 2018.
- Employment Agreements: On February 12, 2018, the company entered into amended employment agreements with the CEO (Martin J. Duvall), CFO (Mark Foletta), and CMO (Asha Das), superseding prior agreements.
- Severance Terms: The new agreements define specific severance packages for "Involuntary Termination" (without cause or for good reason), ranging from 9 to 18 months of base salary continuation, plus health benefits and equity exercise extensions.
Outlook, Risks, and Contingencies
The filing outlines significant financial contingencies related to executive retention and change in control:
- Change in Control: In the event of an involuntary termination surrounding a change in control, executives are entitled to accelerated vesting of time-based stock awards and cash payments equal to 1.0x to 1.5x their target annual bonus.
- Release Requirement: All severance and change-in-control benefits are conditioned upon the executive signing and not revoking a general release of legal claims.
- At-Will Employment: All agreements maintain at-will employment status, allowing termination by either party at any time.
Investor Verification Checklist
- Verify the correct registrant name is Tocagen Inc., not Forte Biosciences, Inc.
- Confirm the total cash outflow for 2017 bonuses ($722,744) and the increased annual salary obligation for 2018.
- Review the full text of the Employment Agreements (filed as exhibits to the 10-K) for specific performance metrics tied to the discretionary bonuses.
- Assess the potential liability for severance payments in the event of a change in control or executive departure.